10-Q quarterly report · filed Nov 12, 2026

ROCKET PHARMACEUTICALS, INC. (RCKT) Q3 2026 10-Q Quarterly Report

Short answer

ROCKET PHARMACEUTICALS, INC. (RCKT) filed its Q3 2026 10-Q quarterly report on Nov 12, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $0 with net income of −$49M.

Q3 2026 key financials · XBRL

Revenue
$0
Net income
−$49M
+2.2% YoY · −140.0% QoQ
EPS (diluted)
−$0.43
+4.4% YoY · −139.8% QoQ

Source: XBRL data from the ROCKET PHARMACEUTICALS, INC. (RCKT) Q3 2026 10-Q on SEC EDGAR. USD.

ROCKET PHARMACEUTICALS, INC. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, no product sales; KRESLADI™ not expected to generate near-term material revenue
  • Operating loss $51.0M vs $52.2M YoY; operating margin not applicable with zero revenue
  • Danon R&D $6.2M vs $5.6M YoY, strongest program investment; RP-A601 R&D $1.0M vs $1.5M
  • Cash, equivalents and investments $279.4M at September 30; operating cash use $124.1M nine-month
  • Hercules financing provided $35M initial draw; runway projected into third quarter 2028, with additional borrowing potentially extending to 2029

Risk Factors

  • New secured debt risk: September 30, 2026 Loan Agreement provides up to $150.0 million, secured by substantially all assets
  • Regulatory and covenant risk: RP-A501 clinical hold or discontinuation raises qualified-cash requirement to 75% of outstanding principal
  • Operational flexibility risk: Loan covenants restrict financing, acquisitions, asset licensing, and strategic transactions
  • Interest-rate risk: Term Loans bear floating interest at the greater of 9.15% or prime rate plus 2.40%
  • Liquidity risk: $50.0 million final tranche requires lenders’ investment committee approval in its sole discretion

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other ROCKET PHARMACEUTICALS, INC. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.